Treace Medical Concepts, Inc.

What they do

Treace develops and markets surgical instruments, implants, and methods for bunion correction and related foot procedures. Its products include the Lapiplasty 3D Bunion Correction System, Adductoplasty Midfoot Correction System, minimally invasive osteotomy systems (Nanoplasty and Percuplasty), SpeedMTP for great toe fusions, and complementary products like SuperBite Compression Screws and SpeedPlate implants. The company sells primarily in the United States through a direct sales force, independent agencies, and stocking distributors to surgeons, ambulatory surgery centers, and hospitals.

Revenue drivers

• Lapiplasty System — Flagship 3D bunion correction system; historically the primary revenue driver with higher average selling prices than newer osteotomy and fusion systems.
• New bunion systems (Nanoplasty, Percuplasty, SpeedMTP) — Launched in Q3 2025; approximately 40% of Lapiplasty surgeon users have adopted at least one of these, up from 35% in Q1 2026, broadening the addressable procedure mix.
• Complementary products (SuperBite, IntelliGuide, SpeedPlate) — Includes compression screws, patient-specific pre-op planning and cut guides, and rapid compression implant platform; newer products in limited release or early adoption, supporting expansion beyond bunions.

Recent performance

Q2 2026 revenue was $45.4 million, down 4% year-over-year from $47.4 million. Net loss improved to $(15.9) million from $(17.4) million; adjusted EBITDA loss was $(3.5) million vs $(3.6) million. Gross margin was 78.5% vs 79.7% in the prior-year period. Year-to-date cash usage fell 57% or $3.6 million; cash, equivalents, and marketable securities totaled $45.6 million as of June 30, 2026.

Strategy

Management is focused on expanding the bunion portfolio to cover a range of procedures, including minimally invasive osteotomy and MTP fusion, to capture more cases and market share. They are investing in direct sales, surgeon education, and product innovation, while working to control costs and improve profitability. The company aims to reduce cash usage by about 50% for full-year 2026 and is positioning for stronger growth in the second half of 2026. They also highlighted a shift toward ambulatory surgery centers as a setting-of-care trend.

Risks

• Macroeconomic pressure on elective surgery demand — Inflation, higher insurance deductibles, and reduced consumer confidence have negatively impacted demand for elective foot and ankle surgeries and may continue to do so.
• Intense competition and procedure shift — Increased competition from Lapidus products and a shift in preferences toward minimally invasive osteotomy and MTP fusion procedures, with competitive products already available, could erode market share.
• Revenue decline and slowing growth — Q2 2026 revenue declined 4% year-over-year, and full-year 2026 guidance calls for a decline of up to 4% compared to 2025, reflecting weak near-term demand.
• Limited liquidity and high leverage — Cash and marketable securities of $45.6 million, with $60.0 million of principal outstanding under credit facilities; the company has an accumulated deficit of $282.8 million and continues to generate operating losses.

Outlook

The company raised full-year 2026 revenue guidance to $204-$212 million (a decline of 4% to 0% versus 2025) from prior $202-$212 million. Adjusted EBITDA loss is now expected to be $3.0-$5.0 million, improved from prior $4.0-$6.0 million. Management expects continued case volume growth and improving year-over-year growth rates in the second half as headwinds annualize.